BioTek reMEDys
www.Biotekrx.com

Asthma Treatments Referral Form

2 Penns Way, Ste#404
New Castle, DE 19720
Phone: (877) 246-9104
Fax: (800) 783-9146

PATIENT INFORMATION (Complete or fax existing chart)

Patient Name: ________________________________
Address: ____________________________________
City, State, Zip: _____________________________
Phone: __________________ 2nd Phone: _____________
DOB: ________ Gender: M F Last 4 S.S:__________
Weight: Ht: Allergies:

PRESCRIBER INFORMATION

Prescriber Name: ____________________________________
State License: _________________ NPI #: _________________
DEA: ________________ Phone: _____________________
Address: _______________________Fax: _________________
City, State, Zip:_____________________________________
Contact Person: ________________ Phone: _______________

INSURANCE INFORMATION - INSTEAD - just send us a copy of the patients prescription / insurance cards (front & back)

Primary Insurance: ______________________________
City, State, Zip: ________________________________
Plan #: _______________________________________
Group #: ______________________________________
Phone: _______________________________________

RX Card (PBM): ______________________________________
BIN: ___________________ PCN: ______________________ _
City, State, Zip: _______________________________________
Group #: ____
Phone: ____

DIAGNOSIS /CLINICAL INFORMATION

☐ J45.40 Moderate Persistent Asthma, Uncomplicated	☐ M30.1 Polyarteritis with lung involvement [Churg-Strauss]
☐ J45.50 Severe persistent asthma, uncomplicated	☐ J33.9 Nasal Polyps, Unspecified ☐ J33.0 Polyp of Nasal Cavity
☐ J45.51 Severe persistent asthma with (acute) exacerbation	☐ L50.1 Idiopathic urticaria
Eosinophil Count: ____________ cells/µL Date of Test:	☐ Other:

Needs by Date: Ship to: Patient Office Other:
Lab Orders:

Fasenra

☐ FASENRA® (benralizumab) 30 mg/mL single-dose prefilled syringe (administered by healthcare professional)
☐FASENRA Pen™ (benralizumab) 30 mg/mL single-dose autoinjector (Self administered)

☐ Loading Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 4 weeks for 3 doses QTY: ___Refills: ___
☐ Maintenance Dose 30 mg/mL solution in a single dose administered by subcutaneous injection once every 8 weeks – QTY: ___ Refills:____

Nucala

☐ Prefilled syringe ☐ Vial ☐ Pen
☐ Inject 100 mg subcutaneously once every 4 weeks
☐ Inject 300 mg (3 separate 100 mg injections) subcutaneously once every 4 weeks
☐ Inject _____ mg (__ separate 100 mg injections) subcutaneously once every __ weeks

Dupixent Pre-filled syringe, package of 2

☐Initial dose: 400 mg SIG: 2 (200 mg/1.14 mL) injections SQ on Day 1
Subsequent (maintenance) dose: 200 mg
SIG: 1 (200 mg/1.14 mL) injection SQ every 2 weeks, starting on Day 15

☐ Initial dose: 600 mg SIG: 2 (300 mg/2 mL) injections SQ on Day 1
Subsequent (maintenance) dose: 300 mg
SIG: 1 (300 mg/2 mL) injection SQ every 2 weeks, starting on Day 15

Other: Initial: ____ Subsequent: Dose_________ Frequency________________
QTY: ___ pk (2 syringes) Refills________

Xolair

☐ Prefilled syringe ☐ Vial Prescription Type: ☐ New start ☐ Restart ☐ Continued Tx Last injection date:______________

SIG ☐ 75 mg/dose every 4 weeks
SIG ☐ 150 mg/dose every 4 weeks
SIG ☐ 225 mg/dose every 4 weeks
SIG ☐ 300 mg/dose every 4 weeks
SIG ☐ 225 mg/dose every 2 weeks
SIG ☐ 300 mg/dose every 2 weeks
SIG ☐ 375 mg/dose every 2 weeks

SIGNATURE

We hereby authorize Biotek Remedys to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral

X ____ Date: _______________

Product Substitution Permitted

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.

If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited.
If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.